News Headlines Article

Pfizer pays $5.2 billion for eczema treatment
USA Today

Pharmaceutical giant Pfizer is adding an eczema treatment to its portfolio with the $5.2 billion acquisition of Anacor Pharmaceuticals.

Pfizer said Monday that it would pay cash for Anacor, whose principal product is an anti-inflammatory topical treatment called crisaborole. Anacor has requested permission from the Food and Drug Administration to sell the treatment after navigating the three-stage drug testing process that’s designed to ensure safety and efficacy.

The treatment could top $2 billion in annual sales at its peak, Pfizer estimated.